Newly Activated Clinical Trials

The following study was recently activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office.

Click the study link below to learn details regarding studies on For more information or questions about a study, email or call 312-355-5112.

Protocol Title: BA3182: An Open-label, Multicenter, Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Efficacy of BA3182, a Bispecific Epithelial Cell Adhesion Molecule (EpCAM)/CD3 Antibody, in Patients with Advanced Adenocarcinoma

PI: Lawrence Feldman, MD, part of the Cancer Center’s Translational Oncology Research Program
Sponsor: NovoCure Ltd.

Protocol Title: ALLO-647-201 : A Randomized, Open-label, Phase 2 Study Evaluating Lymphodepletion With Fludarabine, Cyclophosphamide, And ALLO-647, Vs. Fludarabine And Cyclophosphamide Alone, In Subjects With Relapsed/Refractory Large B-cell Lymphoma (LBCL) Receiving ALLO-501A Allogeneic Car T Cell Therapy

PI: Carlos Galvez, MD, UI Health Division of Hematology and Oncology 
Sponsor: Allogene Therapeutics

Translate »